Filters
cris logo
-
New search Filters
Select from list
Displayed from Show more
You have reached the maximum number of displayed search results.
All results displayed
No results are available for the search performed
Displayed from
You have reached the maximum number of displayed search results.
All results displayed
Loading results
Obtaining statistical data

Projects / Programmes source: ARIS

Novel Mur ligase inhibitors

Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
Keywords
bacterial resistance, new chemical entities
Evaluation (rules)
source: COBISS
Evaluation of bibliographic research performance indicators according to ARIS methodology
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Researchers (8)
no. Code Name and surname Research area Role Period No. of publications
1.  18671  PhD Samo Andrenšek  Chemistry  Researcher  2005 - 2008  151 
2.  05088  PhD Manica Černe  Veterinarian medicine  Researcher  2005 - 2008  106 
3.  23599  PhD Jan Humljan  Pharmacy  Junior researcher  2005 - 2008  21 
4.  09905  PhD Darko Kocjan  Chemistry  Researcher  2005 - 2008  167 
5.  24455  PhD Miha Kotnik  Pharmacy  Junior researcher  2005 - 2008  29 
6.  24465  PhD Luka Peternel  Cardiovascular system  Researcher  2005 - 2008  49 
7.  01661  PhD Tomaž Šolmajer  Chemistry  Researcher  2005 - 2007  380 
8.  01878  PhD Uroš Urleb  Pharmacy  Head  2005 - 2008  382 
Organisations (1)
no. Code Research organisation City Registration number No. of publications
1.  0258  Lek Pharmaceutical Company d.d.  Ljubljana  1732811  8,032 
Abstract
Summary of Objectives1. Cloning of the genes coding for, and purification of, the Mur synthetases from pathogenic species (MRSA, staphylococci, enterococci, H. influenzae,…).2. Kinetic analysis of inhibition of these enzymes3. Determination of the 3D structure of selected enzymes and enzyme-ligand complexes.4. Design, synthesis and bioactivity evaluation of potent inhibitors of these enzymes.5. Preclinical profiling and toxicological evaluation of the best compounds.
Confirmation required
Views history
Favourite